Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million
05 Outubro 2023 - 9:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced an antibody
discovery, option and license agreement with Bayer. Under the terms
of the agreement, Twist Biopharma Solutions, a division of Twist
Bioscience, will leverage its Library of Libraries to conduct
antibody discovery campaigns against targets to be determined by
Bayer. Bayer will have the option to license antibodies discovered
under the collaboration.
“Our ongoing partnership with Bayer leverages the full suite of
our Twist Biopharma Solutions offering of antibody discovery
services to identify the best antibodies for Bayer’s specific
targets,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Twist Bioscience. “By combining the scientific and technical
strengths of each organization, and importantly the level of mutual
trust built over several years working together, we look forward to
identifying and developing new therapies in multiple disease areas
to positively impact patients who need it the most.”
Under the terms of the agreement, Twist will receive payments
connected with the initiation of research and will be eligible to
receive fees associated with research milestones and the exercise
of licensing options. The antibody leads discovered under the
collaboration that enter clinical development qualify for certain
success-based clinical and commercial milestone payments as well as
royalties from product sales. In total, Twist is eligible to
receive up to $188 million in clinical and commercial milestone
payments plus royalties. In return, Bayer receives exclusive rights
to license the antibodies for commercialization in all global
territories.
About Twist Biopharma Solutions (The Biologics Discovery and
Optimization Division of Twist Bioscience)
Twist Biopharma Solutions combines high-throughput DNA synthesis
technology, deep expertise in antibody engineering and in vivo, in
vitro and in silico discovery methods to provide end-to-end
antibody discovery solutions across the preclinical continuum and
tailored to our partners’ specific needs. By leveraging our unique
ability to manufacture DNA at scale, we can construct proprietary
antibody libraries with discovery beginning with either in vivo or
in vitro diversity. Our Library of Libraries gives our partners an
integral and unbiased resource for antibody therapeutic discovery
and optimization. This precise and rational approach to library
fabrication combined with sophisticated bioinformatics and software
expertise expedites antibody discovery by decreasing risk,
increasing speed, and lowering the failure rate for antibody
therapeutic development. Additionally, in vivo discovery approaches
including single B cell screening and hybridoma discovery enable
parallel paths where multiple technology methods can be leveraged
to create a panel of highly diverse antibody leads. Our automated
screening and panning processes enable us to identify high affinity
leads that our partners can move forward into the clinic. We also
offer supporting development capabilities, including IgG
conversion, expression, purification, biophysical characterization,
and functional characterization.
For more information visit:
https://www.twistbioscience.com/products/antibody-discovery/twist-bioscience-and-abveris
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including statements regarding the potential success of the
antibody discovery campaigns, the exercise of licensing options,
the achievement of any clinical or commercial milestones, and
potential product sales, are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may
cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the ability to achieve the expected benefits of Twist
Bioscience’s workforce reduction and reduced investments in DNA
data storage; the ability to attract new customers and retain and
grow sales from existing customers; the ability of Twist to achieve
sufficient revenue to achieve or maintain positive cash flow from
operations or profitability in any given period; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology that could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of significant customers; the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August 7,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005485164/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Generalist
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024